Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men

Journal of the American Geriatrics Society

Volumn 65, Issue 11, 2017, Pages 2362-2368

  Orkaby, Ariela R ^a,b   Gaziano, J Michael ^a,b   Djousse, Luc ^a,b   Driver, Jane A ^a,b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aging; cardiovascular disease; prevention; statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA CAROTENE; CERIVASTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIMARY PREVENTION; PROPENSITY SCORE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; HEART INFARCTION; MORTALITY; ODDS RATIO; RISK ASSESSMENT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY DISEASE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; ODDS RATIO; PROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 85029329248     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.14993     Document Type: Article

References (43)

1. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889–2934.
2. Bibbins-Domingo K, Grossman DC, Curry SJ et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA 2016;316:1997–2007.
3. Zulman DM, Sussman JB, Chen X et al. Examining the evidence: A systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011;26:783–790.
4. Lo-Ciganic WH, Boudreau RM, Gray SL et al. Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults. Ann Pharmacother 2013;47:984–992.
5. Fang MC, Coca Perraillon M, Ghosh K et al. Trends in stroke rates, risk, and outcomes in the United States, 1988 to 2008. Am J Med 2014;127:608–615.
6. 2012 AARP Public Policy Institute Fact Sheet. Available at: http://www.aarp.org/content/dam/aarp/research/public_policy_institute/health/who-relies-on-medicare-factsheet-AARP-ppi-health.pdf (Accessed October 20, 2016).
7. 2010 US Census Briefs. Available at https://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf (Accessed May 20, 2015.).
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
9. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New Engl J Med 1996;335:1001–1009.
10. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–1622.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7–22.
12. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008;359:2195–2207.
13. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–1681.
14. Savarese G, Gotto AM Jr, Paolillo S et al. Benefits of statins in elderly subjects without established cardiovascular disease: A meta-analysis. J Am Coll Cardiol 2013;62:2090–2099.
15. Stone NJ, Intwala S, Katz D. Statins in very elderly adults (debate). J Am Geriatr Soc 2014;62:943–945.
16. Rich MW. Aggressive lipid management in very elderly adults: Less is more. J Am Geriatr Soc 2014;62:945–947.
17. Greenland P, Bonow RO. Interpretation and use of another statin guideline. JAMA 2016;316:1977–1979.
18. Gurwitz JH, Go AS, Fortmann SP. Use of statins in adults older than 75 years-reply. JAMA 2017;317:1081.
19. Cooney MT, Dudina A, D'Agostino R et al. Cardiovascular risk-estimation systems in primary prevention: Do they differ? Do they make a difference? Can we see the future? Circulation 2010;122:300–310.
20. Munson JC, Morden NE, Goodman DC et al. Dartmouth Atlas Project of Medicare Prescription Drug Use. 2013. Available at http://www.rwjf.org/en/research-publications/find-rwjf-research/2013/10/the-dartmouth-atlas-of-medicare-prescription-drug-use.html (Accessed on August 7, 2014).
21. Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: A clinical review. JAMA 2014;312:1136–1144.
22. Steering Committee of the Physicians' Health Study Research Group. Findings from the aspirin component of the ongoing Physicians’ Health Study. New Engl J Med 1988;318:262–264.
23. Sesso HD, Christen WG, Bubes V et al. Multivitamins in the prevention of cardiovascular disease in men: The Physicians’ Health Study II randomized controlled trial. JAMA 2012;308:1751–1760.
24. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. New Engl J Med 1989;321:129–135.
25. Djousse L, Gaziano JM. Egg consumption in relation to cardiovascular disease and mortality: The physicians’ health study. Am J Clin Nutr 2008;87:964–969.
26. Djousse L, Driver JA, Gaziano JM et al. Association between modifiable lifestyle factors and residual lifetime risk of diabetes. Nutr Metab Cardiovasc Dis 2013;23:17–22.
27. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: An example and lesson. Med Care 2007;45(10 Supl 2):S143–S148.
28. Kim DH, Pieper CF, Ahmed A et al. Use and interpretation of propensity scores in aging research: A guide for clinical researchers. J Am Geriatr Soc 2016;64:2065–2073.
29. Elze MC, Gregson J, Baber U et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. J Am Coll Cardiol 2017;69:345–357.
30. Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med 2014;33:1057–1069.
31. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation 2016;133:601–609.
32. Glynn RJ, Koenig W, Nordestgaard BG et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med 2010;152:488–496.
33. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623–1630.
34. Alperovitch A, Kurth T, Bertrand M et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: Population based cohort study. BMJ 2015;350:h2335.
35. Dumurgier J, Elbaz A, Ducimetiere P et al. Slow walking speed and cardiovascular death in well functioning older adults: Prospective cohort study. BMJ 2009;339:b4460.
36. Lo-Ciganic WH, Perera S, Gray SL et al. Statin use and decline in gait speed in community-dwelling older adults. J Am Geriatr Soc 2015;63:124–129.
37. Odden MC, Pletcher MJ, Coxson PG et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med 2015;162:533–541.
38. Tjia J, Cutrona SL, Peterson D et al. Statin discontinuation in nursing home residents with advanced dementia. J Am Geriatr Soc 2014;62:2095–2101.
39. Kutner JS, Blatchford PJ, Taylor DH et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: A randomized clinical trial. JAMA Intern Med 2015;175:691–700.
40. Epstein RM, Peters E. Beyond information: Exploring patients’ preferences. JAMA 2009;302:195–197.
41. American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Guiding principles for the care of older adults with multimorbidity: An approach for clinicians: American Geriatrics Society expert panel on the care of older adults with multimorbidity. J Am Geriatr Soc 2012;60:E1–E25.
42. ClinicalTrials.gov. A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)–Full Text View. Available at https://clinicaltrials.gov/ct2/show/NCT02099123. (Accessed July 26, 2017).
43. Schubert CC, Boustani M, Callahan CM et al. Comorbidity profile of dementia patients in primary care: Are they sicker? J Am Geriatr Soc 2006;54:104–109.